TCGA-75-5126-01A-01R-1755-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.600
- INTERFERON_GAMMA_RESPONSE+0.590
- IL6_JAK_STAT3_SIGNALING+0.570
- INFLAMMATORY_RESPONSE+0.560
- ALLOGRAFT_REJECTION+0.550
- TNFA_SIGNALING_VIA_NFKB+0.530
- COMPLEMENT+0.490
- KRAS_SIGNALING_UP+0.440
- COAGULATION+0.400
- APOPTOSIS+0.340
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.230
- KRAS_SIGNALING_DN-0.140
- HEDGEHOG_SIGNALING-0.120
- MITOTIC_SPINDLE-0.120
- DNA_REPAIR-0.100
- G2M_CHECKPOINT-0.100
- NOTCH_SIGNALING-0.030
- MYC_TARGETS_V2-0.010
- SPERMATOGENESIS-0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD031285_D1.RNA-Seq | EPN | EPN Tumor | 0.919 |
| 2 | MDT-AP-2887 | Med | Medulloblastoma | 0.910 |
| 3 | ERR2208908 | — | — | 0.908 |
| 4 | TCGA-38-4629-01A-02R-1206-07 | — | cohortA1 | 0.903 |
| 5 | EPT0509 | EPN | EPN Tumor | 0.898 |
| 6 | 53D8CF8D-31BA-4CB8-A14F-5C9AB9554F5D | — | — | 0.895 |
| 7 | SRR934945 | — | — | 0.892 |
| 8 | SRR934924 | — | — | 0.884 |
| 9 | f62519fa-7479-4e20-9ae4-d57f8a1e0e64 | — | — | 0.883 |
| 10 | SRR934884 | — | — | 0.882 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.590 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.570 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.560 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.550 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.530 | Inavolisib | — uncovered |
| COMPLEMENT | 0.490 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.440 | Inavolisib | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| APOPTOSIS | 0.340 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.340 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.320 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.320 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.320 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.290 | Inavolisib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.230 | Inavolisib | — uncovered |